Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box only protein 28 (FBXO28) is a member of the F-box protein family characterized by a conserved F-box motif of about 40 amino acids, enabling assembly into the SCF (SKP1–CUL1–F-box protein) E3 ubiquitin ligase complex[1][3][6]. As part of this complex, FBXO28 serves as a substrate-recognition component, interacting with SKP1 and cullin proteins to mediate ubiquitination and subsequent degradation of target proteins, often recognizing phosphorylated substrates[1][3]. FBXO28 has functional roles in regulating protein stability, mitotic progression, cell cycle transitions, and DNA decatenation through regulation of topoisomerase IIα activity[5][8]. Loss-of-function mutations or deletions in FBXO28 are implicated in developmental and epileptic encephalopathy 100, intellectual disability, seizures, and brain abnormalities, particularly as a driver gene in chromosome 1q41q42 microdeletion syndrome[3][4]. FBXO28 is essential for normal neurodevelopment but, as of now, there are no specific drugs known to target this protein directly, nor defined pharmacological mechanisms of action[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box only protein 28 (FBXO28).